Play Earnings CallPlay Earnings Call
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call January 28, 2026 8:30 AM EST
Company Participants
Tram Bui – Head of Investor Relations & Corporate Communications
Helen Torley – President, CEO & Director
Nicole LaBrosse – Senior VP & CFO
Conference Call Participants
Sean Laaman – Morgan Stanley, Research Division
Brendan Smith – TD Cowen, Research Division
Michael DiFiore – Evercore ISI Institutional Equities, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
David Risinger – Leerink Partners LLC, Research Division
Jason Butler – Citizens JMP Securities, LLC, Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Michael Obodai
Presentation
Operator
Good morning. My name is Eric, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme’s Investor Conference Call. [Operator Instructions] Please note, this event is being recorded.
I’ll now turn the call over to Tram Bui, Halozyme’s Vice President of Investor Relations and Corporate Communications. Please go ahead.
Tram Bui
Head of Investor Relations & Corporate Communications
Thank you, operator. Good morning, and welcome to Halozyme’s investor conference call. In addition to the press release issued earlier this morning, you can find a supplementary slide presentation that will be referenced during today’s call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme’s President and Chief Executive Officer, who will provide an update on our business and provide preliminary 2025 revenue estimates in addition to an update to our 2026 to 2028 financial guidance.
On today’s call, we will be making forward-looking statements as outlined on Slide 2. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial
